MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated ...
Dr. André Veillette told Newsweek that their findings could help patients who do not respond to current cancer treatments.
Adaptive Biotechnologies attracts attention as immune medicine innovation, diagnostic advancements, and biotechnology ...
MarketBeat on MSN
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted ...
Host Immune Responses to Arachnid Venoms and Toxins: From Pathophysiology to Therapeutic Development
Arachnology and toxinology have increasingly illuminated the structural, biochemical and evolutionary diversity of venom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results